Celldex Therapeutics, Inc. — Director's Dealing 2010

Jan 22, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2010-01-21

Reporting Person: Davis Thomas Andrew (Sr. VP & CMO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-01-21	Incentive Stock Option	$4.50	A	95000	Acquired	2020-01-21	Common Stock (95000)	Direct

Footnotes

F1: 25% of the options vest on January 21, 2011 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.